PLEOTREATMENT
LIVE

Serial Number

79142345

Owner

PHARNEXT

Attorney

Jeffrey A. Smith

Filing Date

Sep 4, 2013

Add to watchlist:

No watchlists yet
View on USPTO

PLEOTREATMENT Trademark

Serial Number: 79142345 • Registration: 4661507

PLEOTREATMENT is a trademark filed by PHARNEXT on September 4, 2013. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

PHARNEXT (19 trademarks)

46 rue Saint Lazare

Entity Type: 99

Trademark Details

Filing Date

September 4, 2013

Registration Date

December 30, 2014

Published for Opposition

October 14, 2014

Cancellation Date

September 3, 2023

Goods & Services

Training services in the field of medicine and clinical trials; publishing writing and publication of books and texts other than advertising texts; non-downloadable electronic publication of texts in the nature of articles, magazines, brochures in the field of online medicine; educational services, namely, organization and conducting of colloquiums, conferences, conventions, seminars in the field of medicine; teaching in the field of medicine and clinical trials

Creation, compilation, management of databases and central data files in the field of medicine and clinical trials Database management, collection and compilation of information into computer databases in the field of medicine and clinical trials; compilation of statistics; compilation and systematization of data into a central file; public relations; business information, namely, provision of commercial information in the fields of pharmaceutical products and medical and scientific research in the field of pharmaceutical products and clinical trials

Medical services; pharmacy advice; Providing information about the diagnosis and treatment of neurological diseases, Charcot-Mary-Tooth disease, Alzheimer's disease, Parkinson's disease, idiopathic neuropathy, diabetic neuropathy, toxic neuropathy, amyothrophic lateral sclerosis, multiple sclerosis, multiple system atrophy and metabolic disease including diabetes type II, medicines, namely, medicines for the treatment of neurological diseases, Charcot-Mary-Tooth disease, Alzheimer's disease, Parkinson's disease, idiopathic neuropathy, diabetic neuropathy, toxic neuropathy, amyothrophic lateral sclerosis, multiple sclerosis, multiple system atrophy and metabolic disease including diabetes type II, and awareness and information regarding the treatment regarding the aforementioned diseases and illnesses

Pharmaceutical research and development; scientific research for medical purposes in the field of medicine and clinical trials; Scientific and clinical research studies in the fields of medicine, the prevention, treatment and management of illness, health care delivery; chemical and biological analysis, research in chemistry, cosmetology, biology, bacteriology, nutrition, biotechnology; biological research for the diagnosis, prevention and treatment of diabetes and obesity and any other illness; biological research services in the field of chemical, biological and pharmaceutical products; software design and development; scientific laboratory services; research on chemical reagents for medical use, namely, biomarkers

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Mar 31, 2024 DENC
NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Mar 31, 2024 DENA
DEATH OF INTERNATIONAL REGISTRATION
Mar 31, 2024 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Aug 8, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jul 7, 2022 INTS
INVALIDATION PROCESSED
Jul 7, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 16, 2022 INTR
CANCELLED SECTION 71
Jul 16, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Dec 30, 2019 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jul 7, 2017 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jun 8, 2017 NREP
NEW REPRESENTATIVE AT IB RECEIVED
May 26, 2017 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
May 8, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 1, 2015 FICS
FINAL DISPOSITION PROCESSED
Apr 1, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 30, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Dec 30, 2014 R.PR
NOTIFICATION PROCESSED BY IB
Oct 24, 2014 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 14, 2014 NPUB
PUBLISHED FOR OPPOSITION
Oct 14, 2014 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 8, 2014 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 8, 2014 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 24, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 10, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 10, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 10, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 10, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 10, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 10, 2014 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 3, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 3, 2014 CRFA
ASSIGNED TO LIE
Aug 27, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 25, 2014 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 31, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 31, 2014 REAP
REFUSAL PROCESSED BY IB
Mar 14, 2014 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 25, 2014 RFCS
REFUSAL PROCESSED BY MPU
Feb 25, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 25, 2014 RFCR
APPLICATION FILING RECEIPT MAILED
Feb 25, 2014 MAFR
NON-FINAL ACTION WRITTEN
Feb 24, 2014 CNRT
ASSIGNED TO EXAMINER
Feb 21, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 21, 2014 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Feb 19, 2014 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 17, 2014 REPR